The Ras oncoproteins are membrane-associated molecular switches that function to transduce extracellular signals to a panoply of intracellular response mechanisms. Activating mutations in ras genes are present in 15% of all cancers and perhaps as many as 30% of metastatic human cancers. Accordingly, considerable effort has been expended in understanding how Ras proteins work and, by extension, how their transforming activity can be blocked therapeutically (1–6).
No takes yet. Share an insight, caveat, or question.
John Kyriakis (2008) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: